SNX281

Overview

SNX281 is a selective STING agonist, with IC 50 values of 4.1, 4.5, 10.7, and 3.7 μM against human, mouse, rat, and monkey STING , respectively. SNX281 undergoes homodimerization at the STING binding site, triggering a conformational shift of STING from an inactive open state to an active closed state, thereby driving downstream STING -dependent signaling pathways. SNX281 induces type I interferons, IFN-β, TNF-α, IL-6 , cytokine release, T cell responses, and long-lasting immune memory. SNX281 exhibits anti-tumor activity and is applicable to research related to colorectal cancer , melanoma, advanced solid tumors, lymphoma, and ovarian cancer .

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Autoimmune Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > STING | Products > Signaling Pathways > IFNAR | Products > Signaling Pathways > Interleukin Related

Product Information

• Catalog No.: HY-160406
• CAS No.: 2332803-84-4
• Molecular Formula: C20H20ClNO3S
• Molecular Weight: 389.90
• Purity: 98.96%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Availability: In-stock

Source

Original product source